IntrOductIOn
The study of monoclonal antibodies derived from patients with autoimmune diseases has provided important insights to understanding the origin of the humoral response against self-antigens 1-5 and mechanisms of autoantibody pathogenicity. [6] [7] [8] While autoantibodies in rheumatic diseases were first described in rheumatoid arthritis (RA), 9 the molecular characterisation of RA-specific antibodies lagged significantly behind other diseases. The discovery that citrullinated proteins are major targets of the humoral response in RA renewed interest on further characterising the autoantibody repertoire in this disease. 3 10-14 Citrullinated proteins are generated post-translationally by the peptidylarginine deiminases (PADs), a family of five calcium-dependent enzymes (termed PAD1-4 and 6) that convert arginine residues to citrulline residues. 15 At least two major groups of autoantibodies have been linked to the pathogenic role of citrullination in RA: (1) anticitrullinated protein antibodies (ACPAs), which likely drive effector functions by forming immune complexes 16 and (2) anti-PAD4 antibodies that assist the production of citrullinated antigens by enhancing the activity of PAD4. 17 Antibody-mediated PAD4 activation is driven by a subgroup of anti-PAD4 antibodies initially recognised by their cross-reactivity with PAD3. 17 These PAD3/PAD4 cross-reactive antibodies (anti-PAD3/4XR) enhance PAD4 activity by increasing the sensitivity of the enzyme to calcium. Together, ACPAs and antibodies to PAD4 may create a feed-forward loop that promotes effector functions via immune complex formation and autoantigen production.
Initial studies on disease-specific monoclonal antibodies from patients with RA have been centred on ACPAs. 3 11-14 18 A major conclusion from these studies is that ACPAs may originate from polyreactive precursors with their specificities generated as result of antigen-driven affinity maturation. 3 11 18 To gain further mechanistic insights into the development and function of the anti-PAD4 autoantibody repertoire, we determined the molecular features and antigen binding properties of monoclonal antibodies to PAD4 cloned from memory B cells of patients with RA.
MAterIAls And MethOds Patients
All samples were collected after obtaining signed informed consent in accordance with the Johns Hopkins Institutional Review Board. Patients with RA were recruited from the Johns Hopkins Arthritis Center and screened for anti-PAD4 and anti-PAD3/4XR antibodies in serum by immunoprecipitation (IP) as previously described. 17 Peripheral blood anti-PAD4 single memory B cells were purified from three patients who had high titer anti-PAD4 and anti-PAD3/4XR antibodies and used to generate monoclonal antibodies. Detailed descriptions are available in the online supplementary methods. We isolated single anti-PAD4 memory B cells by flow cytometry using recombinant PAD4 tagged with the monomeric fluorescent protein mWasabi (online supplementary figure S1 ). In total, 44 single memory B cells with high binding to mWasabi PAD4 were collected from three patients with RA. Heavy chain (IgH) and corresponding light chain (IgL) variable gene sequences were amplified from 32 cells and used to generate IgG1 monoclonal antibodies. The antibodies were screened by IP (figure 1A), identifying five monoclonal antibodies with specificity to PAD4. Clones 10, 16 and 17 derived from patient 1 were cross-reactive with PAD3, while clones 102 and 104 from patient 3 only recognised PAD4 (anti-PAD4-only antibodies). No antibodies to PAD4 were isolated from patient 2. None of the anti-PAD4 antibodies recognised PAD2 or the PAD from Porphyromonas gingivalis ( figure 1B) .
Based on the IgH V-D-J usage, complementarity-determining region 3 (CDR3) sequence, CDR3 length and the presence of common mutations, monoclonals 10, 16 and 17 were determined to be clonally related ( figure 1C ). The number of somatic hypermutations (SHMs) shared by the IgH of antibodies 10, 16 and 17 are shown in figure 1D . Clones 16 and 17 had the highest similarity with 28 common mutations. Antibody 10 showed 24 mutations, 7 of which were shared by clones 16 and 17. Clones 10 and 17 also shared a related Vκ gene rearrangement (IGKV3D-20/IGKJ4), similar CDR3 sequence and five mutations (figure 1C and E) confirming that these antibodies were derived from the same B cell precursor. However, clone 16 used a different Vκ gene rearrangement (IGKV1-06/IGKJ1) and had a different CDR3 sequence, suggesting the possibility of light chain replacement. 19 20 Antibodies 102 and 104 were not clonally related ( figure 1C ). The enrichment of SHM in all antibodies suggests that they originated from antigen-experienced cells.
Anti-PAd4 autoantibodies arise from autoreactive precursors
To determine whether anti-PAD3 and PAD4 reactivity was due to SHM, we reverted the IgH and IgL chain genes of the antibodies to their germline form, and antigen binding was addressed by IP. Binding to PAD3 and PAD4 by clones 10 and 17, which are the same antibody when reverted to germline, was not affected after germline reversion ( figure 2A) . Similarly, clone 104 retained PAD4 reactivity, although less, in its germline form ( figure 2A ). In contrast, reversion of mutations in clone 16 and 102 led to a complete loss of PAD binding ( figure 2A ). Since IP is not sensitive enough to detect low affinity antibodies or quantitatively compare antibody binding, the binding efficiency of mutated and germline antibodies were additionally compared by ELISA (figure 2B and C). In contrast to IP, all mutated and germline antibodies showed reactivity to PAD4 when compared with control IgG 1 , suggesting that these antibodies were derived from B cell precursors for which reactivity to PAD4 resulted from V(D)J rearrangements. Except for mutated and germline clone 104, which have similar antigen binding, reversion to germline importantly decreased the binding of the other antibodies to PAD4, supporting that their reactivity was enhanced through affinity maturation.
heavy and light chain requirements for PAd binding
While the IgH of antibody 16 is clonally related to antibody 10 and 17, the use of a different light chain suggests that this antibody underwent IgL replacement. 19 20 Nevertheless, it is interesting that this antibody retained binding to PAD4, suggesting that the light chain replacement was insufficient to change its autoreactivity. The study of autoantibodies to DNA has shown that antigen binding can be mediated primarily by the IgH regardless of the IgL. 21 To better understand the independent roles of the mutated heavy and light chains in antigen binding, monoclonals were generated that combined mutated IgH or IgL with either their corresponding germline light and heavy chains or irrelevant chains from a monoclonal with no reactivity to PADs.
Similar to the germline forms of antibodies 10, 17 and 104, reversion to germline of either IgL or IgH retained antigen binding ( figure 2D ). However, hybrid antibodies 10, 17 and 104 that used an irrelevant IgH or IgL completely lost efficient antigen binding ( figure 2D ), suggesting that their reactivity was entirely dependent on the combination of their heavy and light chains either as germline or mutated forms. Antibody 102 lost efficient PAD4 binding when either the heavy or light chain was reverted to germline (figure 2D) or replaced with an irrelevant IgH or IgL (figure 2D), demonstrating that this antibody required both mutated IgH and IgL for efficient binding to PAD4.
While clone 16 containing mutated IgL and germline IgH showed no binding to PADs (figure 2D), mutated IgH retained reactivity to PAD3 and PAD4 when combined with any light chain (figure 2D), suggesting that antigen binding by this clone is largely dependent on mutations in the IgH. This may explain why replacement of the IgL in clone 16 was insufficient to silence antibody reactivity to PADs. It is estimated that 55%-75% of early immature B cells from healthy donors are polyreactive to self-antigens and lipopolysaccharide (LPS). 22 While most of these cells are removed at discrete checkpoints during B cell development, their abnormal survival has been linked to autoimmune diseases. 4 Since anti-PAD4 antibodies reverted to their germline form retained antigen binding, we addressed whether their reactivity to PAD4 may result from polyreactive recognition. In contrast to antibodies present in the serum from a patient with systemic lupus erythematosus that were polyreactive, both mutated and reverted anti-PAD4 antibodies showed no polyreactivity to self-antigens (ssDNA, dsDNA, insulin and cardiolipin) or LPS ( figure 3A) . Similarly, the monoclonal antibodies showed no reactivity to cyclic citrullinated peptides (CCPs) (figure 3B), confirming that they were developed independently of ACPAs.
Functional characterisation of human anti-PAd4 monoclonal antibodies
Autoantibodies that enhance PAD4 activity are strongly associated with more erosive arthritis and interstitial lung disease in patients with RA. 17 23 24 These antibodies were studied as polyclonal IgG purified from the serum of patients with RA, so the functional effects of individual antibody specificities could not be determined. The monoclonal anti-PAD4 antibodies developed here were studied for their individual capacity to activate PAD4 over a physiological range of calcium concentrations in 
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synovial fluid (0.2-1.0 mM), which are suboptimal to fully activate the enzyme in vitro. 17 Using 0.2 mM calcium and enzymatic reactions in the linear range to citrullinate histone H3, a physiological target of PAD4, 25 clone 102 demonstrated the highest agonistic activity (figure 4A, lanes 12), followed by clones 16 and 104 ( figure 4A, lanes 8 and 14, respectively) .
At 0.5 and 1.0 mM calcium, the enhancing PAD4 activity by clones 16, 102 and 104 became more prominent, with clones 10 and 17 also showing some functional activity (figures 4B and supplementary figure S2 ). Importantly, while the germline reversions conserved antigen recognition (figure 2B), these monoclonal antibodies failed to enhance PAD4 activity at 0.2, 0.5 or 1.0 mM calcium ( Figure 4A and B and supplementary figure S2 ). Similarly, antibodies containing mutated IgH from clone 16 combined with its corresponding germline IgL or an irrelevant IgL ( figure 4A and B) , both of which retained PAD reactivity (figure 2A), were also unable to activate the enzyme. At non-physiological saturating calcium concentrations (ie, 5 mM), PAD4 was fully active independently of any antibody (online supplementary figure S3 ).
Since the monoclonal antibodies reverted to germline retained some PAD4 reactivity at high concentrations (figure 2B), we tested their ability to activate PAD4 using increasing amounts of antibody (online supplementary figure S2 ). Unlike mutated anti-PAD4 antibodies, the germline versions required at least 10 times more antibody to induce even minimal PAD4 activity.
Together, these data demonstrate that, while antigen experience is not necessary to produce anti-PAD4 autoantibodies, affinity maturation is required for the generation of efficient agonistic antibodies to PAD4.
Functional antibodies target different epitopes in PAd4
While agonistic anti-PAD4 antibodies were initially recognised by their cross-reactivity with PAD3, 17 it is noteworthy that we identified functional autoantibodies derived from anti-PAD3/4XR-positive patients who only have reactivity to PAD4. This indicates that more than one epitope may be targeted to activate the enzyme. To address whether agonistic anti-PAD4 antibodies target distinct or overlapping epitopes, the antibodies were murinised, and their binding to PAD4 was addressed by ELISA in the presence of increasing amounts of competing human anti-PAD4 antibodies ( figure 4C ). With the exception of antibody 16, the rest of the clones were efficiently generated as murine antibodies, which retained similar PAD4 reactivity as their human counterparts (online supplementary figure S4 ). Antigen binding by the clonally related antibodies 10 and 17 was completely blocked by one another, supporting that they target the same epitope ( figure 4C) . Analysis of the other antibodies, however, is more complex because their considerable differences in binding efficiency ( figure 2C ). Human clone 16, for which binding efficiency is lower than its clonally related antibodies 10 and 17, required 4-10 times more antibody to efficiently block these clones (figure 4C). Antibody 104, which has the highest relative affinity, completely blocked clone 102 and partially blocked clones 10 and 17 at high concentrations but was not significantly blocked by any of other anti-PAD4 antibodies The specificity of mutated and GL anti-PAD4 monoclonal antibodies against ssDNA, dsDNA, LPS, insulin or cardiolipin was addressed by ELISA. The assays were performed in duplicate using serial dilutions of monoclonal antibody (stock 6.8 µM) or human SLE serum as positive control. (B) Reactivity of SHM and GL anti-PAD4 monoclonal antibodies to cyclic citrullinated peptide 3 (CCP3) was addressed by ELISA. The assays were performed in duplicate. AU, arbitrary units; dsDNA, double-stranded DNA; LPS, lipopolysaccharide; OD, optical density; PAD, peptidylarginine deiminase; SHM, somatic hypermutation; SLE, systemic lupus erythematosus; ssDNA, single-stranded DNA.
( figure 4C ). Clone 102 partially blocked antibodies 10 and 17 but was only significantly blocked by clone 104 ( figure 4C ). Based on the distinct recognition of PAD3 (figure 1A), at least two epitopes are likely to be targeted by antibodies that enhance PAD4 activity. Nevertheless, it is possible that antibody 102 may recognised a third epitope that partially overlaps with clones 10, 16 and 17 (PAD3/4XR antibodies) and clone 104 (anti-PAD4-only antibody).
To gain further insights into the structural basis of the interaction between the monoclonal antibodies and PAD4, we attempted to map the regions targeted by the antibodies using PAD4 deletion mutants. PAD4 consists of a C-terminal domain and an N-terminal domain that is divided into subdomains 1 and 2 (online supplementary figure S5A) . 26 Under standard conditions used to IP PAD4, none of the antibodies showed binding to any domain (online supplementary figure S5B ). When the antibody concentration and the incubation time were increased in the IP assays (online supplementary figure S5C ), clone 104 showed reactivity to the N-terminal domain and subdomain 1. However, the other antibodies still failed to react with any subdomain of PAD4 (online supplementary figure S5C ). These findings strongly suggest that the epitope targeted by the majority of functional anti-PAD4 antibodies is structural in nature, requiring folding of the complete molecule.
Agonistic autoantibodies enhance PAd4 activity by regulating the enzyme at calcium-binding site 5
Since agonistic anti-PAD4 antibodies work by lowering the calcium requirement for PAD4 activity, we explored potential sites of interaction using PAD4 mutants that lack the ability to bind calcium at specific sites. PAD4 has five calcium-binding sites designated Ca1-Ca5. Ca1 and Ca2 in the C-terminal domain are required for catalysis, while Ca3-Ca5 are likely relevant to regulate enzyme activity. 26 Aspartic acid residues that coordinate calcium-binding at Ca3 and Ca5 (D 165 ), Ca3 and Ca4 (D 179 ), only Ca4 (D 388 ) and only Ca5 (D 168 ) were changed to alanine. 27 Then, the PAD4 mutants were used to test the functional activity of the antibodies. None of the PAD4 mutants were active in the absence of anti-PAD4 antibodies ( figure 5) . However, the activity of the D 168 A mutant (Ca5) was partially rescued by antibody clones 10, 16, 102 and 104 (figure 5). Interestingly, the enhancing effect of the monoclonal antibodies on the mutant D 168 A was proportional to their activity on wild-type PAD4 (ie, 102>104=16>10) (figures 4B and 5). Together, these data suggest that functional anti-PAD4 antibodies decrease the calcium requirement of PAD4 by regulating the enzyme at Ca5. Although clones 16, 102 and 104 showed some minimal effect on the activity of the mutant D 388 A, Ca5 appears to be the most important site of interaction.
dIscussIOn
Analysis of recombinant antibodies cloned from single new emigrant and mature naïve RA B cells provided initial evidence of defective central and peripheral checkpoints in B cell tolerance in patients with RA. 4 18 In a prior study, these antibodies were shown to be polyreactive to self-antigens and LPS, with a subgroup showing low reactivity to IgG and CCPs. 18 Further studies have shown that ~25% of synovial IgG-expressing B cells are specific to citrullinated antigens in ACPA+ patients with RA. 
Basic and translational research
Despite the considerable understanding of ACPA generation gained through the study of recombinant antibodies cloned from single RA B cells, 3 11 monoclonal antibodies to PAD4 have not previously been identified. The antibodies identified in our current study have unique features that provide novel insights into the understanding of the humoral autoimmune response in RA. In contrast to ACPAs and other antibodies cloned from patients with RA, 3 11 13 14 the antibodies identified in this study are not polyreactive, and antigen recognition was independent of SHM. All clones appear to have emerged from anti-PAD4 B cell precursors (figure 6), which likely bypassed early tolerance checkpoints. Nevertheless, our results demonstrate that affinity maturation is essential for the antibodies to gain efficient agonistic effect against PAD4.
While polyclonal RA sera containing agonistic antibodies to PAD4 were initially identified by their cross-reactivity with PAD3, the cloning of individual antibodies from these patients demonstrated that the functional effect on PAD4 is not driven by antibodies binding to a single epitope. Instead, antibodies targeting different sites on the enzyme, including at least one epitope with structural similarity to PAD3, were able to enhance PAD4 activity.
Although we have cloned human anti-PAD4 agonistic antibodies, the study has some limitations. First, only a 
Figure 6
Genetic characteristics and functional features of RA-derived monoclonal antibodies to PAD4. Antibodies lineage trees were generated by comparison of Ig VH sequences. Monoclonal antibodies were derived from two patients with RA (RA-1 and RA-3). Clonally related antibodies were identified based on sequences derived from a single germline rearrangement characterised by the same V, D and J gene usage, CDR3 length and sequence. The numbers beside the arrows represent the number of mutations acquired in the heavy (VHSHM) and light (VLSHM) chain variable domains. The germline and mutated antibody reactivities are specified, as well as their capacity to enhance PAD4 activity. CDR3, complementaritydetermining region 3; PAD, peptidylarginine deiminase; RA, rheumatoid arthritis; SHM, somatic hypermutation; VH, heavy chain variable domain; VL, light chain variable domain. few antibodies were obtained, which may not represent the complete repertoire of agonistic anti-PAD4 antibodies found in RA. Second, the exact mechanism by which the antibodies enhance PAD4 activity will require the structural definition of the antibody-PAD4 complex. Nevertheless, functional analysis of PAD4 mutants identified Ca5 as a potential site that is commonly regulated by four of the five antibodies. The increase in agonistic activity of antibodies to PAD4 as a result of SHM likely reflects the ability of the antibody to maintain a stable transition state of the enzyme resembling binding of calcium to Ca5. Considering that this transition state is likely favoured when the enzyme is active, it is possible that a conformational state during PAD4 activation may be the primary antigen that drives affinity maturation of functional antibodies. As such, conditions that promote abnormal hyperactivation of PAD4, such as leukotoxic hypercitrullination in neutrophils, 28 29 may lead to both the production of high affinity ACPAs and functional anti-PAD4 antibodies in RA. The finding that ACPAs and antibodies to PAD4 coexist in preclinical RA [30] [31] [32] further supports the hypothesis that conditions of PAD4 hyperactivation may be prevalent in the initiation phase of the disease. Since the generation of agonistic PAD4 antibodies is dependent on the accumulation of somatic mutations and is likely driven by chronic exposure to epitopes of enzymatically active PAD4, this may explain why functional antibodies are largely found in patients with advanced disease. 17 In PAD4, Ca5 is positioned near the surface of subdomain 2 at the interface between the N-terminal and C-terminal domains in a region shown to be important for full activation of the related enzyme PAD2. 26 33 This location may allow Ca5 to be accessible to functional autoantibody binding and potentially to other regulatory molecules. Although pharmacological PAD inhibition has been focused on blocking the catalytic site in the enzyme, the finding that autoantibodies can modulate PAD4 activity by regulating Ca5 offers an additional target for inhibitor development. Molecules designed to interact with Ca5 could potentially block PAD4 hyperactivation with a limited effect on physiological functions that require lower enzyme activity. Similarly, such molecules may be useful to counteract PAD4 interactions with agonistic autoantibodies in patients with RA. In addition to mechanistic insights, the analysis of patient-derived monoclonal antibodies, as we have employed here, offers the opportunity to address pathogenic pathways in erosive RA and to define approaches to offset the consequences of such damage.
